EA200100509A1 - MODIFIED EXOSOMES AND THEIR APPLICATION - Google Patents

MODIFIED EXOSOMES AND THEIR APPLICATION

Info

Publication number
EA200100509A1
EA200100509A1 EA200100509A EA200100509A EA200100509A1 EA 200100509 A1 EA200100509 A1 EA 200100509A1 EA 200100509 A EA200100509 A EA 200100509A EA 200100509 A EA200100509 A EA 200100509A EA 200100509 A1 EA200100509 A1 EA 200100509A1
Authority
EA
Eurasian Patent Office
Prior art keywords
relates
application
vesicles
molecules
exosomes
Prior art date
Application number
EA200100509A
Other languages
Russian (ru)
Other versions
EA004428B1 (en
Inventor
Филипп Бенарош
Элен Венсан-Шнейдер
Памела Штумптнер
Себастьян Амигорена
Кристиан Боннеро
Граса Рапосо
Original Assignee
Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Энститю Кюри
Сантр Насьональ Де Ля Решерш Сьентифик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль, Энститю Кюри, Сантр Насьональ Де Ля Решерш Сьентифик filed Critical Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль
Publication of EA200100509A1 publication Critical patent/EA200100509A1/en
Publication of EA004428B1 publication Critical patent/EA004428B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)

Abstract

Настоящее изобретение относится к областям биологии и иммунологии. Оно относится к мембранным везикулам, содержащим молекулы, в частности антигенные молекулы, с предопределенной структурой, и к их применению. В особенности оно относится к везикулам (экзосомам), содержащим рекомбинантные молекулы главного комплекса гистосовместимости, и их применению в качестве иммуногена или в качестве диагностического или терапевтического средства. Изобретение также относится к способам получения этих везикул, генно-инженерным конструкциям, клеткам и композициям, используемым для осуществления способов согласно изобретению.Международная заявка была опубликована вместе с отчетом о международном поиске.The present invention relates to the fields of biology and immunology. It relates to membrane vesicles containing molecules, in particular antigenic molecules, with a predetermined structure, and to their application. In particular, it relates to vesicles (exosomes) containing recombinant molecules of the major histocompatibility complex, and their use as an immunogen or as a diagnostic or therapeutic agent. The invention also relates to methods for producing these vesicles, genetically engineered structures, cells and compositions used to implement the methods according to the invention. The international application was published together with an international search report.

EA200100509A 1998-11-05 1999-11-04 Modified exosomes and uses EA004428B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9813946A FR2785543B1 (en) 1998-11-05 1998-11-05 MODIFIED EXOSOMES AND USES
PCT/FR1999/002691 WO2000028001A1 (en) 1998-11-05 1999-11-04 Modified exosomes and uses

Publications (2)

Publication Number Publication Date
EA200100509A1 true EA200100509A1 (en) 2001-12-24
EA004428B1 EA004428B1 (en) 2004-04-29

Family

ID=9532412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100509A EA004428B1 (en) 1998-11-05 1999-11-04 Modified exosomes and uses

Country Status (10)

Country Link
EP (1) EP1127110A1 (en)
JP (1) JP2002529074A (en)
CN (1) CN1325441A (en)
AU (2) AU772451B2 (en)
CA (1) CA2349679A1 (en)
EA (1) EA004428B1 (en)
FR (1) FR2785543B1 (en)
IL (1) IL142634A0 (en)
TW (1) TWI224138B (en)
WO (1) WO2000028001A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763524C2 (en) * 2015-06-03 2021-12-30 Инновекс Терапеутикс, С.Л. Exosomes and their use as vaccine

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US7704964B2 (en) 2001-08-17 2010-04-27 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
KR100519384B1 (en) * 2002-08-13 2005-10-06 (주)누백스 Manufacturing method of exosomes using gene transfection and use of the same
CN1313151C (en) * 2002-11-04 2007-05-02 杭州浙大康泰生物技术有限公司 Preparation of high-performance noncellular vaccine and usage
WO2004073319A2 (en) 2003-02-14 2004-08-26 Anosys, Inc. Methods and compounds for raising antibodies and for screening antibody repertoires
WO2005094571A1 (en) * 2004-03-31 2005-10-13 Japan Science And Technology Agency Genetically modified hetero animal and method of measuring exocytosis using the animal
WO2006089572A1 (en) * 2005-02-28 2006-08-31 Charité - Universitätsmedizin Berlin Polyelectrolyte capsules for detecting antigen-antibody-reactions
CN1322115C (en) * 2005-07-06 2007-06-20 清华大学 Ectobody loaded with exogenous ligand molecule and its preparation method and application
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
EP2117305A4 (en) 2007-01-26 2011-03-30 Univ Louisville Res Found Modification of exosomal components for use as a vaccine
ES2927225T3 (en) 2009-04-17 2022-11-03 Univ Oxford Innovation Ltd Composition for delivery of genetic material
EP2450032B1 (en) * 2009-07-01 2018-09-05 MDimune Inc. Microvesicles derived from nucleated, mammalian cells and use thereof
MX2011013452A (en) * 2009-07-02 2012-04-30 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer.
ES2362589B1 (en) 2009-12-28 2012-05-16 Centre De Recerca En Salut Internacional De Barcelona EXOSOMES DERIVED FROM RETICULOCITS INFECTED WITH PLASMODIUM SP., METHOD FOR OBTAINING AND USE.
EP3190186B1 (en) 2011-11-30 2023-12-13 Jörn Bullerdiek Expression of mirnas in placental tissue
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP3052616A4 (en) * 2013-10-02 2017-03-29 Paradigm Biopharmaceuticals Limited A method of producing exosomes
EP2862874B1 (en) * 2013-10-15 2018-12-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for producing polyclonal antibodies using an antigenic composition comprising protein-containing membrane vesicles
DE102014113688A1 (en) * 2014-09-22 2016-03-24 Jacobs University Bremen Ggmbh ANTIGEN-SPECIFIC IMMUNE COLORING OF T CELLS
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
AU2016275046B2 (en) 2015-06-10 2022-07-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
EP3423086A1 (en) 2016-03-03 2019-01-09 Institut Gustave Roussy (IGR) Ptps-based vaccines against cancer
WO2017175253A1 (en) * 2016-04-04 2017-10-12 国立研究開発法人医薬基盤・健康・栄養研究所 Exosome-targeted dna vaccine
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
CN110938670B (en) * 2019-11-07 2023-11-07 南方医科大学南方医院 Application of microbial liquid and serum vesicle reaction in detection of microbial infection
JP2021000093A (en) * 2020-08-05 2021-01-07 国立研究開発法人医薬基盤・健康・栄養研究所 Exosome-targeted DNA vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225553A1 (en) * 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2763524C2 (en) * 2015-06-03 2021-12-30 Инновекс Терапеутикс, С.Л. Exosomes and their use as vaccine

Also Published As

Publication number Publication date
EP1127110A1 (en) 2001-08-29
AU2004203482A1 (en) 2004-08-26
WO2000028001A1 (en) 2000-05-18
EA004428B1 (en) 2004-04-29
FR2785543B1 (en) 2003-02-28
IL142634A0 (en) 2002-03-10
AU1051400A (en) 2000-05-29
CN1325441A (en) 2001-12-05
TWI224138B (en) 2004-11-21
AU772451B2 (en) 2004-04-29
CA2349679A1 (en) 2000-05-18
JP2002529074A (en) 2002-09-10
FR2785543A1 (en) 2000-05-12

Similar Documents

Publication Publication Date Title
EA200100509A1 (en) MODIFIED EXOSOMES AND THEIR APPLICATION
EA200501206A1 (en) DERIVATIONS FROM SURVIVIN PEPTIDES AND THEIR APPLICATION
BR0209777A (en) Stable liquid formulations
DK0922102T3 (en) Hepatocyte growth factor receptor agonists and applications thereof
ES2100174T3 (en) NEW REACTIVE ANTIBODIES WITH HUMAN CARCINOMAS.
DK614987A (en) SYNTHETIC HTLV-III PEPTIDES, PREPARATIONS AND APPLICATIONS THEREOF
DK0527760T3 (en) Methods and Preparations for Vaccination against HIV
AR038568A1 (en) ANTI-A BETA ANTIBODIES AND ITS USE
ATE368054T1 (en) COMPOUNDS AND METHODS FOR MODULATING OCCLUDIN-DEPENDENT TISSUE PERMEABILITY
ES2155070T3 (en) PEPTIDE-CARBOHYDRATE CONJUGATES THAT GENERATE IMMUNITY FOR T-CELLS.
AR003427A1 (en) PEPTIDES RELATED TO DOLASTATIN, PROCEDURE FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE SAME FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITIONS.
EA200001224A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
BR9912975A (en) Compound and compositions for release of active agents, method for obtaining and using them
BR9106394A (en) HUMANIZED CHEMICAL ANTI-ICAM-1 ANTIBODIES, PREPARATION AND USE PROCESSES
UY28424A1 (en) RGI ANTIBODIES AND USES OF THE SAME.
EA200200904A1 (en) STRUCTURES IN SOLUTION AND IN THE CRYSTAL OF THE ACTIVE CENTER MMP-13 AND THEIR APPLICATION
EA200401111A1 (en) TRANS-CAROTINOID BIPOLAR SALTS AND THEIR APPLICATION
ES2194836T3 (en) PEPTIDES FOR USE IN VACCINATION AND INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY.
ATE442439T1 (en) MELANOMA ANTIGENE P15 AND THEIR APPLICATION IN DIAGNOSTIC AND THERAPEUTIC PROCEDURES
AR022236A1 (en) PURIFIED MAMMARY CYTOKINS; REAGENTS AND RELATED METHODS
DE69637571D1 (en) COMPOSITION AND METHOD FOR REINFORCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS
DK0482097T3 (en) Surfactant preparations and methods
TR200102034T2 (en) Using antibodies for anti cancer vaccination
DE60113445D1 (en) SUBSTANCES WITH BRANCHED LINKERMOLEKÜLEN
TR200102877T2 (en) Anti-idiotypic antibodies against antibodies that inhibit the binding of immunoglobulin to its own high affinity receptor.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU